VRB-101
Sources
registry, as of 2026-08-17Stale
https://clinicaltrials.gov/study/NCT07281937
A Study of Weekly Oral Ecnoglutide (VRB-101) in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities. Overall status COMPLETED. Phases PHASE2. Lead sponsor Verdiva Bio Dev Limited. Enrollment 206. Conditions Obesity; Overweight. The aim of this study is to evaluate the efficacy of VRB-101 for body weight reduction compared to placebo in participants who have obesity or overweight with weight-related comorbidities.
ClinicalTrials.gov NCT07281937 protocol and results modules
registry, as of 2026-10-13Stale
https://clinicaltrials.gov/study/NCT07553299
A Study of Weekly Oral Dose of Ecnoglutide (VRB-101) for Weight Maintenance in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities. Overall status TERMINATED. Phases PHASE2. Lead sponsor Verdiva Bio Dev Limited. Enrollment 8. Conditions Obesity; Overweight; Weight Maintenance. The purpose of this study is to identify the weekly oral dose of VRB-101 (oral ecnoglutide) that can effectively maintain body weight in participants with a history of obesity or overweight with weight-related comorbidities.
ClinicalTrials.gov NCT07553299 protocol and results modules
registry, as of 2026-10-13Stale
https://clinicaltrials.gov/study/NCT07628127
A Trial of Oral VRB-103 Alone or in Combination With Oral Ecnoglutide (VRB-101) in Participants With Obesity or Overweight. Overall status RECRUITING. Phases PHASE1. Lead sponsor Verdiva Bio Dev Limited. Enrollment 332. Conditions Obesity; Overweight. The primary objective is to evaluate the safety and tolerability of VRB-103 tablets administered as monotherapy or VRB-103 tablets administered in combination with oral ecnoglutide tablets (VRB-101 tablets) in a single-dose regimen or in a multiple dose regimen.
ClinicalTrials.gov NCT07628127 protocol and results modules